Serum Magnesium Levels in type II Diabetes Mellitus Patients with Special Reference to Long Term Complications of Diabetes (Study of 100 Patients)
Authors/Creators
- 1. MD, Medicine, Assistant Professor, P.D.U Government Medical College, Rajkot, Gujarat, India
- 2. Senior Resident, GMERS Medical College, Vadnagar, Gujarat, India
- 3. MD, Pharmacology, Assistant Professor, P.D.U Government medical college, Rajkot, Gujarat, India
Description
Background and Objectives: Hypomagnesemia can be a consequence of hyperglycemia (as seen in increased urinary magnesium excretion along with glycosuria) and a cause of insulin resistance. The association between diabetes mellitus and hypomagnesaemia is compelling for its wide-ranging impact on diabetic control, its macro and micro-vascular complications, and ultimately on the therapy. Objectives: To estimate prevalence of hypomagnesaemia in patients with type 2 DM and to correlate the serum magnesium concentrations with micro and macrovascular complications of diabetes – retinopathy, nephropathy, neuropathy and ischemic heart disease. Material and Method: An observational study carried out for one year in 100 participants diagnosed with Type 2 diabetes mellitus in the age group of 30–80 years in medicine department, were included in the study. Serum Magnesium levels of all diabetic patients were investigated and compared with long term diabetes complications like diabetic retinopathy, nephropathy and neuropathy. Serum Magnesium levels were also compared with comorbid conditions like hypertension, Lipid profile and HbA1C for poor glycaemic control. Statistical analysis were carried out for correlation and test of significance. Result: Among 100 participants, males were 47% and females were 53 % with mean age of 55.04 ± 11.2 years. The average duration of diabetes in study population was 5.5 years and most of the patients were received oral hypoglycemic drugs for their diabetes treatment. 29% of participants had hypomagnesemia (serum Mg≤ 1.7mEq/L). Among the patients having hypoglycemia, 23.3% of participants were having hypertension, 31% were having retinopathy, 37.9% were having nephropathy and 69% were having neuropathy. In our study, retinopathy and neuropathy were significantly correlated with hypoglycaemia (p value <0.05). Among lipid profile, Serum triglyceride and serum HDL cholesterol were significantly and inversely correlated with hypomagnesemia. Poor glycemic control in patients with hypomagnesemia were also established due to significant correlation between High HbA1C level and hypomagnesemia. Conclusion: Hypomagnesemia was significantly associated with diabetic retinopathy and neuropathy, poor glycemic control and lipid profile abnormalities. Benefits of Mg supplementation on metabolic profile in diabetic subjects have been found in most, but not all clinical studies, and larger prospective studies are needed to support the potential role of dietary Mg supplementation as a possible public health strategy in diabetes risk.
Abstract (English)
Background and Objectives: Hypomagnesemia can be a consequence of hyperglycemia (as seen in increased urinary magnesium excretion along with glycosuria) and a cause of insulin resistance. The association between diabetes mellitus and hypomagnesaemia is compelling for its wide-ranging impact on diabetic control, its macro and micro-vascular complications, and ultimately on the therapy. Objectives: To estimate prevalence of hypomagnesaemia in patients with type 2 DM and to correlate the serum magnesium concentrations with micro and macrovascular complications of diabetes – retinopathy, nephropathy, neuropathy and ischemic heart disease. Material and Method: An observational study carried out for one year in 100 participants diagnosed with Type 2 diabetes mellitus in the age group of 30–80 years in medicine department, were included in the study. Serum Magnesium levels of all diabetic patients were investigated and compared with long term diabetes complications like diabetic retinopathy, nephropathy and neuropathy. Serum Magnesium levels were also compared with comorbid conditions like hypertension, Lipid profile and HbA1C for poor glycaemic control. Statistical analysis were carried out for correlation and test of significance. Result: Among 100 participants, males were 47% and females were 53 % with mean age of 55.04 ± 11.2 years. The average duration of diabetes in study population was 5.5 years and most of the patients were received oral hypoglycemic drugs for their diabetes treatment. 29% of participants had hypomagnesemia (serum Mg≤ 1.7mEq/L). Among the patients having hypoglycemia, 23.3% of participants were having hypertension, 31% were having retinopathy, 37.9% were having nephropathy and 69% were having neuropathy. In our study, retinopathy and neuropathy were significantly correlated with hypoglycaemia (p value <0.05). Among lipid profile, Serum triglyceride and serum HDL cholesterol were significantly and inversely correlated with hypomagnesemia. Poor glycemic control in patients with hypomagnesemia were also established due to significant correlation between High HbA1C level and hypomagnesemia. Conclusion: Hypomagnesemia was significantly associated with diabetic retinopathy and neuropathy, poor glycemic control and lipid profile abnormalities. Benefits of Mg supplementation on metabolic profile in diabetic subjects have been found in most, but not all clinical studies, and larger prospective studies are needed to support the potential role of dietary Mg supplementation as a possible public health strategy in diabetes risk.
Files
IJTPR,Vol13,Issue6,Article37.pdf
Files
(578.8 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:a8c35bcde4968fd9d0e1acffdfc1a2ce
|
578.8 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-06-27
Software
References
- 1. Hans, Chetan P., et al. "Magnesium Deficiency and Diabetes Mellitus." Current Science, JSTOR 2002;83(12): 1456–63., 2. Nadler JL, Buchnan T, Natarajan R, Antonipillai I, Bergman R, Rude RK. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension. 1993; 21: 1024-9. 3. Paolisso G, Barbagallo M. Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium. Am J Hypertens. 1997 Mar;10(3):346-55. 4. Ninomiya T. Japanese Legacy Cohort Studies: The Hisayama Study. J Epidemiol. 2018 Nov 5;28(11):444- 451. 5. Wawrzyniak, A.J. Framingham Offspring Study. In: Gellman, M.D., Turner, J.R. (eds) Encyclopedia of Behavioral Medicine. Springer, New York, NY. 2013. 6. Larsson SC, Wolk A. Magnesium intake and risk of type 2 diabetes: a meta-analysis. J Intern Med 2007; 262:208-14. 7. Schulze MB, Schulz M, Heidemann C, Schienkiewitz A, Hoffmann K, Boeing H. Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. Arch Intern Med 2007;167:956–65. 8. Djurhuus, Mogens & Skøtt, P & Vaag, Allan & Hother-Nielsen, Ole & Andersen, Pernille & Parving, H & Klitgaard, N. Hyperglycaemia enhances renal magnesium excretion in Type 1 diabetic patients. Scandinavian journal of clinical and laboratory investigation. 2000; 60:403-9. 9. Yajnick CS, Smith RF, Hockaday TDR, Ward NI. Fasting plasma magnesiu m concentration and glucose disposal in diabetes. BMJ 1984; 288: 1032-4. 10. Walti MK, Zimmermann MB, Hurrell RF. Low plasma magnesium in type-II diabetes. Swiss Med Wkly. 2003; 133: 289-92. 11. Alzaida A, Dinneen SF, Moyer TP, Rizza RA. Effects of insulin on plasma magnesium in noninsulin dependent diabetes mellitus – evidence for insulin ressitance. J Clin Endocrinol Metab. 1995; 80: 1376-81. 12. Resnick LM. Cellular ions in hypertension, insulin resistance, obesity, and diabetes: a unifying theme. J Am Soc Nephrol 1992;3:S78–S85. 13. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The ARIC study. Am Heart J. 1998; 136: 480-90. 14. Abraham AS, Rosenmann M, Kramer M. Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction. Arch Intern Med. 1987; 147: 753-5. 15. Kareem I, Jaweed SA, Bardapurkar JS, Patil VP, et al. Study of magnesium, glycosylated hemoglobin and lipid profile in diabetic retinopathy-Indian J Clin Biochem. 2004 Jul;19(2):124-7. 16. Grafton G, Baxter MA, Sheppard MC. Effects of magnesium on sodium dependant inositol transport. Diabetes. 1992; 41: 35-9. 17. Dipankar Kundu, Manish Osta, Tridibeswar Mandal, Ujjwal Bandyopadhyay, Debes Ray, and Divyendu Gautam, et al. Serum magnesium levels in patients with diabetic retinopathy-J Nat Sci Biol Med. 2013 Jan-Jun; 4(1): 113–116. 18. Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, Kawabata H, Niihata K, Okada N, Isaka Y, Rakugi H, Tsubakihara Y, et al. Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of endstage renal disease-Diabetes Care. 2012 Jul;35(7):1591-7. 19. Corsonello A, Ientile R, Buemi M, Cucinotta D, Mauro VN, Macaione S, Corica F. Serum ionized magnesium levels in type 2 diabetic patients with microalbuminuria or clinical proteinuria. Am J Nephrol. 2000 MayJun;20(3):187-92. 20. Lipids in association with serum magnesium in diabetes mellitus patients Hamid Nasri, Hamid-Reza BaradaranBratisl Lek Listy 2008; 109 (7) 21. Kareem I, Jaweed SA, Bardapurkar JS, Patil VP, et al. Study of magnesium, glycosylated hemoglobin and lipid profile in diabetic retinopathy-Indian J Clin Biochem. 2004 Jul;19(2):124-7. 22. Corsonello A, Ientile R, Buemi M, Cucinotta D, Mauro VN, Macaione S, Corica F. Serum ionized magnesium levels in type 2 diabetic patients with microalbuminuria or clinical proteinuria. Am J Nephrol. 2000 MayJun;20(3):187-92. 23. Halder, Subrata & Roy, Koushik & Biswas, Kaushik & Biswas, Priyankar & Sarkar, Ramita. (2016). Study of relation of serum magnesium level with glycemic control in diabetes mellitus. International Journal of Research in Medical Sciences. 4429-4433.